GlassScriptPhysician profile
Suvarchala Devi Dara
NPI 1477764900
$5,300.70
in general payments reported to CMS, 2019-2025
38 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $140 · 2021: $227 · 2022: $972 · 2023: $1,243 · 2024: $1,059 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,448 · Education: $87.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,448.08 |
| Education | $87.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.26 | 2019-2025 | Farxiga, Andexxa, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.97 | 2019-2025 | Jardiance |
| Cvrx, INC. | $435.60 | 2023-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $413.26 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $394.00 | 2021-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $362.47 | 2022-2024 | Assure Wcd |
| Amgen INC. | $338.50 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $215.59 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $196.40 | 2025 | |
| Novo Nordisk INC | $155.45 | 2022-2025 | Ozempic, Wegovy |
| Pfizer INC. | $152.09 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $139.05 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $137.72 | 2022-2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $135.19 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.24 | 2019-2023 | Lifevest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $82.27 | 2023 | Inpefa |
| Amarin Pharma, INC. | $63.36 | 2020-2022 | |
| Boston Scientific Corporation | $50.70 | 2021-2025 | Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $50.03 | 2019-2025 | Aveir |
| Baxter Healthcare | $48.84 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $44.58 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $42.18 | 2019 | |
| Bard Peripheral Vascular, INC. | $36.54 | 2024-2025 | Venclose Maven Catheter |
| Inspire Medical Systems, INC. | $35.75 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $31.27 | 2025 | Uptravi |
| Bardy Diagnostics, INC. | $28.00 | 2020-2021 | |
| Ge Healthcare | $27.78 | 2021 | |
| Scpharmaceuticals INC. | $27.73 | 2024 | |
| Angiodynamics, INC. | $27.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.67 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $18.36 | 2025 | Arexvy, Shingrix |
| Intercept Pharmaceuticals, INC. | $17.89 | 2025 | |
| Philips North America LLC | $15.40 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Edwards Lifesciences Corporation | $13.51 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.49 | 2025 | |
| Irhythm Technologies, INC. | $13.09 | 2023 | Zio Xt Patch |
| Gilead Sciences, INC. | $12.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suvarchala Dara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.